Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW873140 plus optimized background therapy versus placebo in treatment-experienced HIV-1 patients with dual/mixed tropic drug-resistant virus
2005-001246-16Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing GW873140 plus OBT with Placebo plus OBT (2 arms). Primary endpoints: Antiviral activity at 24 and 48 weeks and Superiority in plasma HIV-1 RNA AAUCMB. Started Jun 2005; status: completed.
02
Drugs
aplaviroc
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001246-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001246-16.